Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples